For a stretch of the 1990s, homocysteine looked like it might become as famous as cholesterol. A cheap blood test, a plausible mechanism, and a wave of studies all pointed the same direction: this ordinary amino acid seemed to be quietly wrecking arteries, and lowering it looked like an easy win against heart disease. Then the trials came in, and the story got more complicated. The test never disappeared, but what a good clinician uses it for has changed.
What homocysteine actually is
Homocysteine is an amino acid, a byproduct your body makes while breaking down methionine, a different amino acid you get from protein in food. Under normal conditions it does not stick around. Vitamin B12, vitamin B6, and folate (vitamin B9) act as the machinery that converts homocysteine into other compounds the body needs, mainly methionine again or a related molecule called cysteine. In a healthy person, that conversion happens fast enough that only a small amount of homocysteine is ever found circulating in the blood, generally somewhere in the range of 5 to 15 micromoles per liter, according to Cleveland Clinic.
The problem starts when that breakdown machinery slows down. If you are short on B12, B6, or folate, homocysteine cannot be processed as quickly, and it accumulates. That is the core reason the test exists: it works as a sensitive readout of whether those B vitamins are doing their job at the tissue level, sometimes flagging a functional shortage before a direct vitamin test would, as Testing.com notes.
The discovery that built a theory
The reason homocysteine ever became a cardiovascular story traces back to a rare genetic disease called homocystinuria, in which the body cannot break homocysteine down at all. In the 1960s, researchers noticed that children born with this condition, who carry extremely high homocysteine levels their entire lives, developed severe atherosclerosis and died of cardiovascular disease decades before it should have appeared, sometimes in their teens or twenties. Pathologist Kilmer McCully reported on this pattern in 1969 and proposed that homocysteine itself was damaging the arteries directly, an idea now known as the homocysteine hypothesis of heart disease.
That theory had obvious appeal. If an extreme, genetic version of high homocysteine caused early, aggressive artery disease, it was reasonable to ask whether milder, common elevations were doing the same thing more slowly to everyone else. Through the 1990s, observational studies backed the idea up: people with higher homocysteine tended to have more coronary artery disease, in a relationship that looked almost linear, with one review estimating that every 10 percent rise in homocysteine tracked with a similar rise in coronary risk. Because B vitamins reliably lower homocysteine and fortifying food with folic acid is cheap and safe, the hypothesis arrived with a built-in solution ready to test.
What the trials actually found
That test is where the story turned. Multiple large randomized trials gave people B-vitamin supplements specifically to lower their homocysteine and then watched for heart attacks and strokes. The supplements worked as designed: homocysteine levels came down. Cardiovascular event rates mostly did not. As MedlinePlus puts it plainly, even though high homocysteine can damage arteries, studies have shown that in most cases lowering homocysteine levels does not reduce the risk of heart attack or stroke. Testing.com describes the same gap: the association between homocysteine and cardiovascular disease is real, but current evidence does not support treating it as an independent, modifiable risk factor the way LDL cholesterol or blood pressure are treated.
The likely explanation is that homocysteine is more a marker of the underlying trouble than a cause of it, or one contributor among many that supplementation cannot fully correct once damage is under way. Either way, the practical consequence was swift: no major medical organization recommends homocysteine as a routine cardiovascular screening test for the general population. It moved out of the "next cholesterol" conversation and into a narrower, still genuinely useful role.
Where the test still earns its place
That narrower role is real, not a consolation prize. A homocysteine test still has clear jobs: confirming a functional B12 or folate shortfall, since homocysteine can rise before a direct vitamin level drops out of range, which is why providers often pair it with a methylmalonic acid test to tell a B12 problem apart from a folate one; screening newborns for homocystinuria, the original and still-standard use; monitoring chronic kidney disease, since the kidneys help clear homocysteine and declining function raises it independent of vitamin status; and taking a selective look at unexplained cardiovascular risk in someone with a strong family history but none of the usual suspects, no smoking, normal cholesterol, normal blood pressure. MedlinePlus also notes that in older adults with elevated homocysteine, targeted B-vitamin therapy may help slow cognitive decline, an area still being studied rather than settled.
What it is not good for is a stand-in for a full cardiovascular workup, and it is not the same test as MTHFR genetic testing. MTHFR is a common gene variant that can impair folate metabolism and contribute to persistently high homocysteine, but confirming it requires a separate genetic test, not the homocysteine level itself. A high homocysteine result that does not respond to straightforward B-vitamin supplementation is one common reason a provider might order that gene test next.
Reading a result
Reference ranges vary somewhat by lab and by age and sex, but the general categories used by Cleveland Clinic and echoed by Testing.com look like this:
| Category | Approximate range | |---|---| | Normal | About 5 to 15 µmol/L | | Moderate elevation | 15 to 30 µmol/L | | Intermediate elevation | 30 to 100 µmol/L | | Severe elevation | Above 100 µmol/L |
A handful of ordinary factors move the number before any disease does. Levels tend to climb with age, run higher in men than in women until menopause narrows the gap, and rise with smoking. Certain medications, including methotrexate, some anti-seizure drugs, and some diuretics, can push it up, while high-dose B-vitamin supplements taken before the draw can push it artificially low. None of this is a reason to distrust the test; it is a reason to read a single number in context rather than as a verdict.
Common questions
Does a standard blood panel include homocysteine? No. It is not part of a complete blood count, a comprehensive metabolic panel, or a standard lipid panel. A provider has to order it specifically, usually because of symptoms or a targeted concern about B-vitamin status or cardiovascular risk.
Should a healthy person with no symptoms ask for this test? Generally not as routine screening. No major guideline recommends homocysteine testing for the general population, largely because the trial evidence does not show that acting on a mildly elevated result changes cardiovascular outcomes for most people.
If B vitamins lower homocysteine, why doesn't that lower heart attack risk? Because the trials that tested this directly found the two do not move together the way the original hypothesis predicted. Large randomized studies gave people B-vitamin supplements, watched homocysteine fall as expected, and still saw no consistent drop in heart attacks or strokes. The honest reading is that homocysteine tracks with risk more than it drives it, at least at the moderate elevations most people have.
What actually causes a high result besides low B vitamins? Chronic kidney disease, hypothyroidism, certain medications, smoking, and normal aging can all raise homocysteine independent of vitamin status. That is one reason a single elevated result is interpreted alongside symptoms and other labs rather than on its own.
Can I lower my homocysteine through diet alone? Often, yes, if the cause is a mild vitamin shortfall. Folate-rich foods include leafy greens, legumes, and fortified grains; B12 comes from eggs, dairy, fish, and meat. A provider can help decide whether food changes are enough or whether supplementation makes sense.
Homocysteine did not turn out to be the second cholesterol. It turned out to be something more modest and, in its own way, more interesting: a real signal that the body's B-vitamin machinery is under strain, worth reading carefully and in context, rather than a dial anyone should try to force down and expect a guaranteed reward.
